CVS Health Corp vs Novo Nordisk A/S — how do they compare? CVS Health Corp trades at $93.54 (market cap $119.58B), while Novo Nordisk A/S trades at $45.93 (market cap $207.85B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CVS | NVO | |
|---|---|---|
Market Cap | $119.58B | $207.85B |
Sector | Health | Health |
52-Week High | $110.60 | $63.98 |
52-Week Low | $65.51 | $35.29 |
Enterprise Value | $181.93B | $222.55B |
Dividend Yield | 2.84% | 3.81% |
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →